A comprehensive analysis of the price and efficacy of obeticholic acid

The name of the drug Obeticholic acid (Obeticholic acid) has gradually entered the public eye in recent years, especially in the treatment of primary cholangitis, a rare and serious autoimmune disease. When the small bile ducts in the liver are damaged and bile cannot flow normally, it will accumulate inside the liver, causing damage to liver tissue. This damage can lead to scarring of the liver, gradual decline in function, and even an increased risk of liver cancer.

In the treatment of primary cholangitis, obeticholic acid often works hand in hand with another drug called ursodeoxycholic acid (UDCA). For those patients for whom UDCA alone is ineffective, or who are unable to use UDCA for various reasons, obeticholic acid has become their new hope. Before obeticholic acid was approved for clinical use, a series of studies had demonstrated its significant effect in reducing bilirubin and alkaline phosphatase (ALP) levels in the blood of patients with primary cholangitis. Reductions in these two substances are viewed by the medical community as a positive sign of improved liver health.

For Chinese patients, obeticholic acid is still a relatively unfamiliar name. Since it has not yet been approved for marketing in China, it cannot be included in the medical insurance system, which makes many patients worried about its price. According to information from overseas markets, the original drug of obeticholic acid is expensive. Common specifications such as5mg30 tablets and 10mg30 tablets may cost thousands of dollars per box. Fortunately, with the continuous advancement of generic drug technology, more affordable generic drugs of obeticholic acid have appeared in overseas markets. Their ingredients are highly similar to the original drugs, but the price has been significantly reduced, bringing hope to more patients.